Molecular Partners AG
As of Oct 22, 2026, Molecular Partners is in Stage 4, the downtrend phase, now in week 2 (since Oct 15, 2026). It closed at $3.61, 29.6% below its 52-week high and below its 200-day average, which is falling.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MOLN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MOLN among Biotechnology196th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …196 | MOLN | Stage 4 · wk 2 | 52 | −16.1% |
Molecular Partners: quick answers
What stage is Molecular Partners in?
As of Oct 22, 2026, Molecular Partners (MOLN) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 15, 2026 and is in week 2. What the four stages mean
Is Molecular Partners in an uptrend?
No. Molecular Partners is in a Stage 4 downtrend. It trades 13.8% below its 200-day average, which is falling.
How far is Molecular Partners from its 52-week high?
Molecular Partners closed at $3.61 on Oct 22, 2026, 29.6% below its 52-week high of $5.13. Its 52-week low is $3.54.
How has Molecular Partners performed over the past year?
As of Oct 22, 2026, Molecular Partners is down 2.5% over the past year and down 14.5% so far in 2026.
Which sector and industry is Molecular Partners in?
Molecular Partners is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.